TO
GI – Milan, 23 July. – Sigma Tau Pharma was sold to Baxalta incorporated for 900 million dollars. The operation was completed today by Sigma Tau Finanziaria, a holding company in the pharmaceutical sector, which sold the subsidiary's 100% to Baxalta, the leading American group in the biopharmaceutical sector.
The transaction has obtained clearance from the competent competition authorities, on the basis of theagreement signed last 12 
May. Sigma Tau and Baxalta have also signed a production agreement according to which Sigma Tau will continue to produce the anticancer drug Oncaspar at the Indianapolis plant in the USA for 5 years. (AGI) .
